We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+15.79%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$280M
AUM Growth
–
Cap. Flow
+$264M
Cap. Flow
% of AUM
94.32%
Top 10 Holdings %
Top 10 Hldgs %
44.86%
Holding
69
New
69
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$19.8M |
| 2 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$19.8M |
| 3 |
Biogen
BIIB
|
+$13.7M |
| 4 |
AbbVie
ABBV
|
+$11.1M |
| 5 |
THOR
THORATEC CORPORATION
THOR
|
+$10.8M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.98% |
| 2 | Financials | 1.53% |
| 3 | Industrials | 0.94% |
| 4 | Technology | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$165B
| $21.4M | 7.65% |
+285,000
| New | +$19.8M |
|
|
2
State Street Health Care Select Sector SPDR ETF
XLV
$42.9B
| $20.5M | 7.33% |
+370,000
| New | +$19.8M |
|
|
3
Biogen
BIIB
$30.9B
| $14.8M | 5.3% |
+53,000
| New | +$13.7M |
|
|
4
AbbVie
ABBV
$465B
| $11.9M | 4.24% |
+225,000
| New | +$11.1M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $10.5M | 3.74% |
+124,000
| New | +$9.81M |
|
6
McKesson
MCK
$104B
| $10.2M | 3.63% |
+63,000
| New | +$9.68M |
|
|
THOR
7
DELISTED
THORATEC CORPORATION
THOR
| $10.1M | 3.6% |
+275,000
| New | +$10.8M |
|
8
Bristol-Myers Squibb
BMY
$129B
| $9.59M | 3.43% |
+180,500
| New | +$9.19M |
|
9
Amgen
AMGN
$209B
| $9.02M | 3.22% |
+79,000
| New | +$8.99M |
|
10
Agilent Technologies
A
$39.6B
| $7.61M | 2.72% |
+185,934
| New | +$7.07M |
|
11
UnitedHealth
UNH
$382B
| $7.53M | 2.69% |
+100,000
| New | +$7.18M |
|
12
Thermo Fisher Scientific
TMO
$214B
| $7.52M | 2.69% |
+67,500
| New | +$6.71M |
|
|
GENT
13
DELISTED
GENTIUM SPA ADS
GENT
| $6.82M | 2.44% |
+119,500
| New | +$5.31M |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
| $6.79M | 2.42% |
+51,000
| New | +$6.12M |
|
15
Intuitive Surgical
ISRG
$127B
| $6.72M | 2.4% |
+157,500
| New | +$6.63M |
|
16
Illumina
ILMN
$29.5B
| $6.11M | 2.18% |
+56,797
| New | +$5.2M |
|
17
Bausch Health
BHC
$1.75B
| $5.52M | 1.97% |
+47,000
| New | +$5.15M |
|
|
TMH
18
DELISTED
Team Health Holdings Inc
TMH
| $5.35M | 1.91% |
+117,500
| New | +$5.23M |
|
19
Cardinal Health
CAH
$53.7B
| $4.28M | 1.53% |
+64,000
| New | +$3.91M |
|
|
AET
20
DELISTED
Aetna Inc
AET
| $4.27M | 1.53% |
+62,300
| New | +$4.07M |
|
|
AGN
21
DELISTED
Allergan plc
AGN
| $4.12M | 1.47% |
+24,500
| New | +$3.83M |
|
22
CVS Health
CVS
$135B
| $3.92M | 1.4% |
+54,750
| New | +$3.52M |
|
|
WBA
23
DELISTED
Walgreens Boots Alliance
WBA
| $3.68M | 1.31% |
+64,000
| New | +$3.72M |
|
24
Humana
HUM
$43.9B
| $3.41M | 1.22% |
+33,000
| New | +$3.23M |
|
25
Puma Biotechnology
PBYI
$398M
| $3.26M | 1.17% |
+31,500
| New | +$1.85M |
|
Similar funds
AAM
SGI
ACM
BCM
ISS
PP
FDP
GAM
Rock Springs Capital Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Rock Springs Capital Management, which disclosed 69 positions worth $280M. Its ten largest holdings account for 45% of the portfolio.
Its largest position is Gilead Sciences: 285,000 shares worth $21.4M.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, followed by Financials and Industrials.
- Rock Springs Capital Management's largest Q4 2013 buy was Gilead Sciences: 285,000 shares worth $21.4M.
- Rock Springs Capital Management's ten largest holdings make up 45% of its $280M portfolio in Q4 2013.
- Rock Springs Capital Management disclosed 69 positions in Q4 2013, its first 13F filing on record.
Based on Rock Springs Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.